{"id":"W1968618374","doi":"10.1007/s10637-015-0230-x","title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Pharmaceuticals International; Takeda Oncology","keywords":"Ixazomib; Medicine; Rash; Pharmacodynamics; Multiple myeloma; Pharmacokinetics; Adverse effect; Internal medicine; Proteasome inhibitor; Pharmacology; Gastroenterology; Oncology; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003904837,0.0002349081,0.0004410842,0.0003377935,0.00005595008,0.00002354016,0.0001609097,0.00009237502,0.00004455287],"category_scores_gemma":[0.0009327977,0.0002022376,0.00005114517,0.0005589144,0.0002517352,0.0004639695,0.00006846458,0.0001927816,0.00003902761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001930362,"about_ca_system_score_gemma":0.002248431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005677428,"about_ca_topic_score_gemma":0.00009423977,"domain_scores_codex":[0.9974112,0.0001350716,0.0005937429,0.0004280769,0.001106422,0.00032551],"domain_scores_gemma":[0.9980568,0.0001094017,0.0001879659,0.0003226822,0.0003722458,0.0009509204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002047947,0.01418747,0.9074607,0.0002050618,0.0002061347,0.0003862795,0.01374511,0.0008258672,0.05223007,0.002961972,0.002443252,0.003300159],"study_design_scores_gemma":[0.1592202,0.01556879,0.6314496,0.001018319,0.0001408271,0.0002289674,0.01097085,0.008607889,0.1104513,0.06079212,0.0006067888,0.0009443527],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963408,0.00007795195,0.00001794298,0.001150928,0.00006966718,0.001868265,0.00002657443,0.00004716993,0.0004007436],"genre_scores_gemma":[0.9897766,0.000001866391,0.008850298,0.0002451608,0.0001286109,0.0002737492,0.0002868918,0.0000237752,0.0004130437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.276011,"threshold_uncertainty_score":0.8247012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07539078866375962,"score_gpt":0.3640018764683731,"score_spread":0.2886110878046134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}